Quick context
Melanotan II
影响色素沉着及其他黑皮质素信号；未批准产品的安全性和纯度不确定。
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Back to all 64 profiles
Community/research information only未获 FDA/EMA 批准
Community protocol · Melanotan II
Melanotan II: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: MT-2 · MT-II · MT-2 Melanotan 2 Acetate · Melanotin Receptor Type 2 · Synthetic melanocortin peptide
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Community/research information only
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amount status
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: anecdotal.
Timing
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycle/duration
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Non-selective melanocortin receptor agonist
Melanotan II is classified as “Non-selective melanocortin receptor agonist”. 影响色素沉着及其他黑皮质素信号；未批准产品的安全性和纯度不确定。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
非选择性黑皮质素作用
这项研究考察某物质如何同时激活多种黑皮质素受体亚型而非单一亚型,这可能带来更广泛但更难预测的效应,类似万能钥匙而非单一钥匙。研究中会平行测量多种身体反应。
黑皮质素受体激活
这项研究考察激活黑皮质素受体如何影响色素沉着或性唤起信号,如同根据受体亚型控制不同身体功能的开关。研究中测量皮肤色素沉着或生理唤起标志物。
色素沉着与光反应
这项研究考察皮肤色素细胞如何对使皮肤变深的信号做出反应,这可能降低对阳光的敏感度,类似于照片曝光越多颜色越深。研究人员通常测量研究参与者的皮肤色素水平和光敏感度。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
美容项目论坛
用户比较使用与黑皮质素相关的物质后晒黑或皮肤变化情况,通常依据分享的照片而非医学检查。这类帖子无法证明经过审查的安全性,对于未获批的变体尤其如此。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
商家营销宣传
商家常常以宽泛的功效宣称、与竞品的对比表格以及客户评价来推广产品。这类营销言论受销售利益驱动,并不构成独立的科学疗效证据。
Adverse effects and risk boundaries
- 黑皮质素作用可引起恶心、潮红、血压变化、头痛、不希望的色素沉着及性方面不良反应；非选择性类似物不确定性更大。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 非典型痣/皮肤癌风险、未控制高血压、心血管疾病、阴茎异常勃起风险及妊娠均需医学评估。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据获批用途，可评估皮肤、血压、恶心、色素变化及适应证相关终点。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
轶事性
未获批准产品的安全性和纯度尚不明确,且缺乏可靠的人体数据。
Published evidence
相关说法主要依赖个人经历分享和商家宣传,而非对照研究。
Melanotan II是一种非选择性、未获批准的前体物质,阿法诺肽和溴美拉肽这两种已获批药物均由其开发而来。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
未获 FDA/EMA 批准
没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA warning letter: listed peptide substances
- Primary/technical sourceTGA — Melanotan II products found to be inconsistently dosed
- Community referenceMelanotan II — Peptide Dosing Protocols